FIELD: biotechnology.
SUBSTANCE: disclosed is an antibody molecule which binds to PD-L1 and CD137 and is capable of inducing CD137 agonism. Said antibody molecule contains a CDR-based PD-L1 binding site and a CD137 binding site, which is located in the CH3 domain of the antibody molecule. Also disclosed are nucleic acids coding antibody molecules, expression vectors and a host cell containing said nucleic acids, a method of producing the antibody molecule. Invention also relates to a pharmaceutical composition containing the antibodies according to the invention, and to the use of said antibodies for treating cancer in an individual.
EFFECT: antibodies according to the present invention have high pharmacological activity and safety and can be used, for example, for treating diseases such as cancer.
19 cl, 30 dwg, 33 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
